Providing vaccines in a pandemic timeframe, pDNAVACC-Ultra™ family of vectors, is a rapidly deployable set of DNA vaccination tools that can be readily adapted to any antigens in a one to two-week antigen turnaround service.
pDNAVACCUltra™ DNA Vaccine Vectors
• Enhanced antigen expression in mammalian cells
• Compliance with FDA guidance
• Improved antibody response
• Improved antibody avidity
• Kanamycin or RNA-OUT (antibiotic free) selectable markers
• Improved DNA backbone for maximum plasmid production (>2.5g/L)
Description:
NTC’s pDNAVACCUltra™ vectors represent a quantum leap forward in expression, immunogenicity, destination targeting (secreted, endosomal, membrane-anchored, proteasomal, native), and regulatory compliance. These vectors have proven effective at providing high-level protection (70-100%) in animals, against a variety of microbial antigens: plague, anthrax, influenza, rabies, and other virus. They can be used alone, or in combination with other forms of antigen for prime-boost regimens. The high levels of expression attained from the Ultra-CMV promoter and transcriptional modifications regularly beat the expression and immunogenicity of previous generation ‘Gold Standard’ vectors.
Features:
• Optimized, chimeric promoter-intron (SV40-CMV-HTLV-1 R-U5-synthetic intron) for max expression/immunogenicity
• Superior E. coli plasmid production yields from improved origin of replication (>2.5g/L)
• Destination targeting – secreted, endosomal, membrane anchored, proteasomal, native – for directed, or mixed presentation
• Compliance with regulatory guidance for DNA vaccine vectors – all non-essential sequences removed, backbone optimized for non-homology to human genome
• Seamless cloning of antigens, and antigen cloning services available (RapidVACC)
• Optional antibiotic-free backbones and Type 1 interferon activating RNA elements (RNAe).
Vector Information: pDNAVACCultra3:
Vector Features: pDNAVACCUltra3, a typical DNA vaccine plasmid backbone: trpA prokaryotic terminator: 3308-16; pUC replication origin: 23-1037; Kanamycin resistance marker: 1045-1965; Fd gene VIII prokaryotic terminator:1972-2015; tonB bidirectional terminator: 2023-2060; CMV enhancer: 2078-2635; CMV promoter: 2636-2755; Untranslated leader (exon 1): 2756-2807; Intron: 2808-2933; Kozak sequence (exon 2):2934-2942; TPA N-terminal targeting tag: 2943-3011; SapI cloning cassette: 3012-3048; GPI C-terminal targeting tag: 3049-3147; Eukaryotic terminator: 3158-3297.
|
